CMMB — Chemomab Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Brief: Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial
U.S. STOCKS ON THE MOVE-Thermo Fisher, Palo Alto, American Eagle Outfitters
U.S. STOCKS ON THE MOVE-Kinnate, Walt Disney, VF Corp
U.S. STOCKS ON THE MOVE-Chemomab, Arcellx, Generac
U.S. STOCKS ON THE MOVE-Sirius XM, Spirit Airlines, Canoo
Chemomab rises on FDA's 'fast track' tag for liver disorder treatment
Brief: Chemomab Therapeutics Receives FDA Fast Track Designation For Cm-101 For The Treatment Of Primary Sclerosing Cholangitis
Brief: Chemomab Therapeutics Discloses Receipt Of Nasdaq Notice Regarding Minimum Bid Price Requirement
Brief: Chemomab Therapeutics Presents Data Reinforcing Clinical Potential Of CM-101
U.S. STOCKS ON THE MOVE-PureCycle, Amazon.com, Dollar Tree
U.S. STOCKS ON THE MOVE-PureCycle, Walt Disney, Chipotle Mexican Grill
U.S. STOCKS ON THE MOVE-Harley-Davidson, Eightco, Beauty Health
Chemomab soars on positive data from trial of fatty liver drug
Brief: Chemomab Therapeutics Reports Positive Data From Secondary Analysis Of Phase 2A Liver Fibrosis Trial In NASH Patients At EASL 2023
Chemomab Therapeutics Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Chemomab Therapeutics Announces Q1 2023 Financial Results, Provides A Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 4 cents a share - Earnings Preview
Brief: Chemomab Therapeutics To Discuss Q1 2023 Financial Results